Associated Papers
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
41055698 (PubMed )
Supplement: BLOOD_BLD-2024-027009-mmc6.xlsx › Sheet_1
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S et al.
Blood Advances, 2023
Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents.
Sedlarikova L et al.
Frontiers in Oncology, 2020
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.
Vikova V et al.
Theranostics, 2019
30809292 (PubMed )
Supplement: thnov09p0540s1.pdf
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
Jones D et al.
Leukemia, 2017
Select a paper to view details